RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma
- 15 August 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (4) , 1151-1158
- https://doi.org/10.1182/blood-2003-11-4079
Abstract
Multiple myeloma (MM) plasma cells (PCs) express receptor for hyaluronan-mediated motility (RHAMM), a hyaluronan-binding, cytoskeleton and centrosome protein. The most abundant RHAMM isoforms in MM are full-length RHAMM (RHAMMFL) and the splice variant RHAMM-exon4. We separately examined the significance of RHAMM expression, and isoform balance, in 2 groups of MM patients. In oligonucleotide microarray experiments (n = 210, Arkansas), increasing RHAMM mRNA expression in MM PCs is strongly associated with osteolytic bone lesions (P < .001), and event-free (P = .05) and overall (P = .04) survival. Semiquantitative determination of RHAMM isoform expression (Alberta, Canada) used capillary electrophoretic detection and measurement of RHAMM-exon4/RHAMMFL reverse-transcriptase-polymerase chain reaction (RT-PCR) products. RHAMM isoforms are rarely expressed concurrently in single MM PCs; the pattern of isoform expression, at the single-cell level, is approximated in larger numbers of cells by the RHAMM-exon4/RHAMMFL ratio. Absolute RHAMM expression and the RHAMM-exon4/RHAMMFL ratio are only partially correlated in MM PCs; in cell lines, absolute RHAMM expression is elevated in mitosis, while RHAMM ratios remain stable. Temporal examination of MM patients9 peripheral blood reveals that the RHAMM-exon4/RHAMMFL ratio increases with disease burden. The RHAMM-exon4/RHAMMFL ratio in diagnostic bone marrow samples (n = 101, Alberta) is an independent prognostic factor. Thus, expression and splicing of RHAMM are important molecular determinants of disease severity in MM. (Blood. 2004;104:1151-1158)Keywords
This publication has 31 references indexed in Scilit:
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentationBlood, 2002
- Multiple myeloma: evolving genetic events and host interactionsNature Reviews Cancer, 2002
- Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM VariantsBlood, 1999
- The Hyaluronan Receptor RHAMM Regulates Extracellular-regulated KinasePublished by Elsevier ,1998
- CD34+ Cells in the Blood of Patients With Multiple Myeloma Express CD19 and IgH mRNA and Have Patient-Specific IgH VDJ Gene RearrangementsBlood, 1997
- The characterization of a human RHAMM cDNA: conservation of the hyaluronan-binding domainsGene, 1996
- Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformationCell, 1995
- Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motilityThe Journal of cell biology, 1992